Is KALA or KNSA more undervalued in 2026?

CirclFi compares KALA BIO, Inc. (KALA) and Kiniksa Pharmaceuticals Interna (KNSA) using 13 institutional-grade valuation models. KALA has a Quality of Company score of 3.3/10 while KNSA scores 5.5/10.

Which is a better buy — KALA or KNSA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KALA and KNSA valuations compare?

KALA at $2.23 and KNSA at $48.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KALA vs KNSA Valuation Comparison 2026 — Intrinsic Value Analysis

KALA

Pharmaceutical Preparations

KALA BIO, Inc.

Quality

3.3

out of 10

Value Trap

SAFE

Price

$2.23

Last close

Models

7/13

Active

KNSA

Pharmaceutical Preparations

Kiniksa Pharmaceuticals Interna

Quality

5.5

out of 10

Value Trap

SAFE

Price

$48.38

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	KALA Fair Value	KALA Upside	KNSA Fair Value	KNSA Upside
Bayesian DCF	Intrinsic	$0.06	-97.4%	$6.16	-87.3%
Earnings Power Value	Intrinsic	—	—	$9.70	-79.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$4.24	+89.9%	$8.51	-82.4%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KALA vs KNSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KALA vs KNSA — Which Stock Is More Undervalued?

KNSA scores higher with a 5.5/10 quality rating vs KALA's 3.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing KALA BIO, Inc. (KALA) and Kiniksa Pharmaceuticals Interna (KNSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KALA currently trades at $2.23 with a QOC of 3.3/10, while KNSA trades at $48.38 with a QOC of 5.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).